Radioactive drug takes aim at Hard-to-Treat sarcoma
NCT ID NCT07156565
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a radioactive drug called [Ac225]RTX-2358 in 30 adults with advanced soft tissue sarcoma that has come back or stopped responding to prior treatment. The drug is given as an IV injection once every 8 weeks for up to 6 doses. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Participants will also receive a diagnostic imaging agent to help identify tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A radioactive drug called [Ac225]RTX-2358, given by IV every 8 weeks
What this could lead to
If it works, this could point toward a new treatment option for advanced sarcoma that has stopped responding to other therapies.
What could go wrong
This is an early phase 1 trial with only 30 people, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77230, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloane Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Princess Margaret Cancer Centre
NOT_YET_RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••